New norm? Three biotechs pencil in $100M IPOs
Three biotechs have tagged onto an impressive streak of IPOs this year, penciling in $100 million each for their public debuts.
The S-1 from 4D …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
